Kirsten Drejer: “The time is right”
With big decisions on the horizon the time is right for a change of the guards at the helm of Danish biotech company Symphogen, says departing CEO Kirsten Drejer. From September 1st she will become an ordinary member of the board in the company she helped found in 2000 and has led since.
BY LOUISE WENDT JENSEN
Few had seen it coming – certainly at this point – but late last week the announcement came that Kirsten Drejer is stepping down as CEO of biotech company Symphogen from September 1st, leaving the day-to-day operation of the company to current CFO Martin Olin.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
